TORONTO, June 22, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the Company has entered into an innovative research collaboration with the Centre for Addiction and Mental Health (“CAMH”), a top psychiatric research hospital based in Toronto, Canada. Mindset will sponsor a preclinical study at CAMH on its lead asset, MSP-1014, a novel and patented second generation psilocybin-like compound that is being prepared for First-in-Human studies alongside psilocybin.